KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) Research & Development (2016 - 2025)

Xylem (XYL) has 16 years of Research & Development data on record, last reported at $60.0 million in Q4 2025.

  • For Q4 2025, Research & Development rose 3.45% year-over-year to $60.0 million; the TTM value through Dec 2025 reached $226.0 million, down 1.74%, while the annual FY2025 figure was $226.0 million, 1.74% down from the prior year.
  • Research & Development reached $60.0 million in Q4 2025 per XYL's latest filing, up from $52.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $61.0 million in Q3 2023 and bottomed at $47.0 million in Q3 2022.
  • Average Research & Development over 5 years is $54.9 million, with a median of $54.5 million recorded in 2022.
  • Peak YoY movement for Research & Development: rose 29.79% in 2023, then fell 9.84% in 2024.
  • A 5-year view of Research & Development shows it stood at $52.0 million in 2021, then rose by 3.85% to $54.0 million in 2022, then grew by 11.11% to $60.0 million in 2023, then dropped by 3.33% to $58.0 million in 2024, then increased by 3.45% to $60.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $60.0 million in Q4 2025, $52.0 million in Q3 2025, and $58.0 million in Q2 2025.